You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday.
They remind you to not talk during the movie, but when I saw “Project Hail Mary” last week, I was so alarmed that Ryan Gosling placed two Eppendorf tubes next to each other that I said, aghast, “He didn’t balance the centrifuge — that would have wrecked it…” while my non-scientist friends cracked up.
That one scientific flub aside, it’s still one of the best book-to-film adaptations I’ve seen, maybe ever.
“Project Hail Mary” reviews, job offers for a scientific production designer role on the next blockbuster movie, AI tips: [email protected]
Insilico Medicine CEO on the company’s AI philosophy
I’ve always been a little confused about Insilico Medicine, one of the biggest and longest-running AI drug companies. I’ve never fully understood what it does or its popularity. But earlier this week, the company inked a deal with Eli Lilly for $115 million upfront and $2.75 billion in total potential payments. (You can read more about the deal and some Insilico basics in my story here.)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
